GILD
Gilead Sciences, Inc.
- Operating income, 2025
- $10.0B
- YoY, 2025
- +503.0%
- 5-year CAGR
- +19.7%
- 10-year CAGR
- −7.6%
Operating income
Operating income by fiscal year
| Period | Operating income | YoY |
|---|---|---|
| 2025 | $10.0B | +503.0% |
| 2024 | $1.7B | −78.1% |
| 2023 | $7.6B | +3.8% |
| 2022 | $7.3B | −26.1% |
| 2021 | $9.9B | +143.6% |
| 2020 | $4.1B | −5.0% |
| 2019 | $4.3B | −47.7% |
| 2018 | $8.2B | −41.9% |
| 2017 | $14.1B | −19.9% |
| 2016 | $17.6B | −20.5% |
| 2015 | $22.2B | +45.4% |
| 2014 | $15.3B | +237.4% |
| 2013 | $4.5B | +12.8% |
| 2012 | $4.0B | +5.8% |
| 2011 | $3.8B | −4.4% |
| 2010 | $4.0B | +12.3% |
| 2009 | $3.5B | +31.8% |
| 2008 | $2.7B | +23.7% |
| 2007 | $2.2B | — |